TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of steps in the HIV care cascade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28 Day Ventilator Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: %SFA in the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: level of proinflammatory factors (IL - 6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: level of leukocytes (WBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: level of CRP (c reactive protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf): Area Under the Plasma Concentration-time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t): Area Under the Plasma Concentration-Time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of E7820
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Antibody Against Protein D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to P2Y12 Platelet Inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Beta-Blocker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Statin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Angiotensin System Blocker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Hypotensive Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regression Rate of Polyp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: drop in oxygen saturation during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Change in HERV-K Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FEV1 (Forced expiratory volume in one second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glasgow Outcome Scale Extended
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: All fatal and nonfatal acute coronary and stroke events
Endpoint domain: Mortality/survival
Primary endpoint: Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Treatment Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Vitamin B12 Deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of depressive symptoms (assessor-rated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of self-report mood symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neuroimaging changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Score on the Mindful Attention Awareness Scale (MAAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline appendicular skeletal muscle mass at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline appendicular skeletal muscle mass at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline gait speed at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with sight-threatening CNV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Visual Analog Score for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer Yield Per 1,000
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity (True Positive Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: False-positive Recall Rate
Endpoint domain: Adverse events/effects
Primary endpoint: ocular safety assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of FF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of FF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thyrogen-stimulated serum Tg measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Eczema Area and Severity Index (EASI75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post-treatment improvement of peripheral artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pulpal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cervico-thoracic angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantitative rT-PCR of stool microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrarater reliability of DAS28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success or treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline UDI Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interleukin-10 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pelvic floor distress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence or absence of criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connor Davidson Resilience Scale Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Withdrawal Assessment Tool (WAT-1) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of space closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection rate of Sonozoid enhanced ultrasound for focal liver lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Change in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Z Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: TCD-detected microemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute level of platelet inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Cardiac Event
Endpoint domain: Mortality/survival
Primary endpoint: Time to Major Cardiac Event
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Alcohol use in the last 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana use in the last 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV sexual risk behavior in the last 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rectal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in LDCT screening rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of joints with active arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak plasma concentration of IX-01 (C max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of peak plasma concentration of IX-01 (t max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC 0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in feeling of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in feeling of restlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of PLHIV linked to HIV care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: insulin sensitivity (glucose Rd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal phospho-STAT5 level after GM-CSF stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: STAT5 Phosphorylation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GM-CSF Signaling Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of delir prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Radiation Dermatitis Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of Bone Mineral Density (BMD) Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BOLD Activation in Right ACC During Parametric Flanker Task tDCS Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Accuracy on N-Back Working Memory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Reaction Speed on N-Back Working Memory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose-Limiting Toxicity (DLT) During Dose Escalation Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With DLT During Dose Expansion Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of BRCA1/2 mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Uptake of genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of mutation carriers not fulfilling criteria for genetic testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall high risk HPV prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain assessment using the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depression and Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Survey score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Structured Clinical Interview for DSM-IV (SCID-IV)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to pain as assessed by Neonatal Facial Coding Score (NFCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1C (A1C) at Week 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54
Endpoint domain: Adverse events/effects
Primary endpoint: Child HBsAg at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: composite outcome of death, severe retinopathy of prematurity, chronic lung disease of prematurity, necrotizing enterocolitis
Endpoint domain: Mortality/survival
Primary endpoint: composite of death or neurodevelopmental impairment
Endpoint domain: Mortality/survival
Primary endpoint: Depression at One Point in the Study
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Quantity of alcohol use in a typical weekend
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Estimated peak blood alcohol content (peak BAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Frequency of binge drinking episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Number of alcohol-related consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients With Chemotherapy-induced Sensory Peripheral Neuropathy ≥ Grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Weight and height measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T cell glycolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T cell respiratory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Opioid consumed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for redo surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change in QT-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total amount of propofol transferred to breast milk in 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of fospropofol transferred to breast milk in 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction (%) of the maternal dose transferred to breast milk in 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of serious medical errors
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of All-cause Mortality or Hospitalization for Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Response rate, CR + PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AEs and changes in laboratory values and vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in cytokine composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunologic measurements in tumor, tumor stroma and blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic print of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of Life in Severe Dementia
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pathological tumor regression grade (pTRG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Airway responsiveness (PC20) to methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway responsiveness (PD15) to inhaled mannitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway responsiveness (PC20) to deep inhalation methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Died or Went on Mechanical Ventilation From Day 1 Through Day 29 Based on Overall mFAS
Endpoint domain: Mortality/survival
Primary endpoint: Time-weighted Average (TWA) Change in Viral Load in Nasopharyngeal (NP) Samples Based on Seronegative mFAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Death or Mechanical Ventilation Based on Seronegative mFAS
Endpoint domain: Mortality/survival
Primary endpoint: Integrity of the cerebrovascular autoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of P. vivax
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Fibrinogen Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetics measured by AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Most Frequently Reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Regression of retinal neovascularizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Time for donor site to heal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylation of CpG islands in genomic DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Changes in FVC From Baseline to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Changes in FVC% Predicted From Baseline at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of pre-visit differential diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of clinical and/or parasitological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects achieving antibody titer above 1/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in peripheral fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in fasting lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of impaired glucose tolerance and insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Presenting With Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Death As Outcome
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With ACR 20 Response at Day 169
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive HCV-RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: inadvertent shivering post surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of soluble transferrin receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of alpha-1-acid glycoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-first HF rehospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in adherence to quality metrics for HF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) Based on Independent Reviewer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) Based on Investigator Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity Specific Balance Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity and Specificity of US for Diagnosis and Severity Grading for SOS/VOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of CEUS for Diagnosis and Severity Grading for SOS/VOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes